Table 2 Treatment characteristics

Primary tumor

  Group 1 (PT-Ø* < 2.5 cm, n = 17)

73.8

  Group 2 (2.5 – 4.5 cm, n = 52)

79.2

  Group 3 (4.5 – 6.0 cm, n = 20)

84.6

  Group 4 (> 6.0 cm, n = 8)

90.0

Nodes

61.2

Nodes electively**

45

Fractional dose (Gy)

1.8 bid

  Interval

8 h

Radiation treatment duration (days, median, range)

30 (28 – 37)

Chemotherapy before radiotherapy (patients, %)

91 (91)

  Cycles (n, median, range)

2 (1 – 4)

  Carboplatin

76 (76)

  Cisplatin

15 (15)

  Gemcitabine

40 (40)

  Pemetrexed

36 (36)

  Navelbine

12 (12)

  Etoposide

2 ( 2)

  Taxotere

1 ( 1)

Durvalumab, consolidation post radiotherapy (patients, %)

  Started

36 (36)

  Completed at 12 months, without toxicity

11 (11)

  Incomplete, until now well tolerated

12 (12)

  Premature termination

13 (13)

    PD-L1-negativity

4 (4)

    Progression of disease

4(4)

    Toxicity

2 (2)

    Intercurrent death

2 (2)

    Patient request

1 (1)